next generation HIV maturation inhibitors (Hetero/DFH Pharma)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Namenext generation HIV maturation inhibitors (Hetero/DFH Pharma)
Drug Alias Nameanti-HIV program (Hetero Drugs)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlycosaminoglycan inhibitorsHuman immunodeficiency virus type 1 protease inhibitors
TargetsHuman immunodeficiency virus type 1 proteaseGlycosaminoglycan
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesIndia
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesHetero Drugs Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDFH Pharma IncHetero Drugs Ltd
Active IndicationsN/A
Inactive IndicationsHIV Infections

Other Information

ATC CodeN/A
Related LinksN/A